Technical Articles
Abelacimab
Molecular Pathology and New Advances in Targeted Therapy for Factor XI Deficiency
This article systematically elaborates on the discovery history, molecular genetic basis, and unique clinical manifestations of coagulation factor XI deficiency (hemophilia C), analyzing the pathological puzzle of its lack of correlation between bleeding tendency and FXI levels as an autosomal recessive genetic disorder.
View details
- Drug Research
- Fully Human Anti-Factor XI Monoclonal Antibody
- Abelacimab
- 1













